ClinicalTrials.gg
CompletedNCT07062302Updated Jul 14, 2025

Effectiveness of Low-Level Light Therapy for Vocal Fatigue

An interventional study of photobiomodulation in Vocal Fatigue, sponsored by Chinese University of Hong Kong. Completed at 1 site in Hong Kong. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-14.

Sponsored by Chinese University of Hong Kong · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 3 months after the study started (first participant enrolled Mar 2024, registered Jun 2025).
Phase
Not applicable
Study type
Interventional
Enrollment
22
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this phase 2 clinical trial is to examine the effectiveness of photobiomodulation in patients with vocal fatigue.

The main question it aims to answer is whether photobiomodulation is able to alleviate vocal fatigue in patients with diagnosed vocal fatigue.

Participants will ask to receive photobiomodulation treatment for 12 sessions over a three week period.

Read the detailed description

Vocal fatigue is a common complaint of patients with voice disorder and is related to functional and/or organic voice disorders. Professional voice users, such as teachers and singers and actors, are particularly prone to vocal fatigue. It has been reported that vocal fatigue also associated with limitation to voice activities and participation. In patients with vocal fatigue, experience of inflammation and muscle pain are among possible symptoms and manifestations of the condition.

In literature, various definitions have been suggested for vocal fatigue. Welham and Maclagan defined vocal fatigue as the negative vocal adaptation led by prolonged use of voice, and it can consist of perceptual, acoustic or physiologic components of undesirable or unexpected functional changes in the laryngeal mechanism.

In exploring the nature of vocal fatigue, Titze capitalised on a generally recognised mechanism of muscle fatigue which comprised of a peripheral component and a central component. Specifically, for the peripheral component, fatigue may take place at the myo-neural junction, muscle membrane and endo-plasmic reticulum (i.e., the transmission mechanism) or the muscle filaments (i.e., the contractile mechanism), where depletion or accumulation of biochemical substances such as glycogen occurs.

Low-level light therapy (LLLT), also known as photobiomodulation (PBM) therapy, has been developed as a therapeutic procedure which involves the exposure to low levels of red and near infrared light to cells or tissues. It has been approved by the Food and Drug Administration (FDA) of the United States for aesthetic and medical purposes.

Ever since, it has been established as a non-invasive and safe approach for a number of medical processes, such as reducing inflammation, relieving pain, wound healing, skeletal muscle repair and treating neurological disorders. Specifically, its effectiveness on treating muscle fatigue was investigated with the focus placed on muscles such as bicep braquialis, quadriceps and orbicularis oris.

These studies utilised the feature of LLLT to interact with muscle tissues and therefore provide physiological and/or therapeutics effects to reduce muscle fatigue and enhance muscle performance. Relating this to the fatigue resulting from prolonged voice use at the laryngeal level, it is possible for LLLT to be developed as a treatment approach for vocal fatigue.

In a Phase 1 study, the potential effectiveness of using LLLT in vocal fatigue treatment by applying red or infrared Lights to healthy individuals following vocal loading tasks was explored. The authors concluded that red light might be effective in improving vocal fatigue on aspects of acoustic, aerodynamic, and self-perceptual markers.

The proposed study will be a Phase 2 behavioural study-controlled trial on the effectiveness of LLLT on treating vocal fatigue.

The primary objective of this study is to investigate the effectiveness of lower-level light therapy on reducing vocal fatigue on self-perceptual phenomena exhibited by participants, as well as acoustic and aerodynamic changes in voice.

Vocal Fatigue Index (Hong Kong-Chinese Version) (VFI(HK)) will be used as the primary outcome measurement methods. Perceptual evaluation of voice, acoustic measurement, aerodynamics evaluation (by maximum phonation time (MPT)), vocal symptoms scale and Voice Handicap Index (VHI-30) will be used as secondary outcome measurements.

The current study will be a preliminary clinical trial to identify the therapeutic efficacy of PBM on laryngeal muscles as a new treatment for patients with vocal fatigue. It could act as a pilot study and results obtained could be a foundation for Phase 3 RCT studies to investigate using LLLT to treat vocal fatigue.

02

Conditions studied

  • Vocal Fatigue

Browse trials for

Keywords

  • vocal fatigue
  • voice disorders
  • photobiomodulation
  • low-level light therapy
03

In context

Voice Disorders

77 studies on the registry are indexed under Voice Disorders; 17 are open to participants now.

This study's enrollment of 22 is below the median of 41 across 54 interventional studies indexed under Voice Disorders.

Browse Voice Disorders studies →

Lead sponsor

Chinese University of Hong Kong is the lead sponsor of 1,454 studies on the registry; 474 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged over 18 years old
  • Meeting the diagnosis of vocal fatigue as per the VFI-HK
  • Able to make
  • Have not received any voice therapy before

Exclusion criteria

Exclusion Criteria:

  • History of photoallergy
  • Significant medical or chronic diseases
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    Photobiomodulation arm

    Device: photobiomodulation

Interventions

  • Devicephotobiomodulation

    The output of the photobiomodulation device is listed as below: * Irradiation size: 15 cm × 10 cm * Dual-wavelength: 660 nm + 850 nm * Optical power density: 10 - 15 mW/cm2 * Dose density: 6J/cm2

    Also known as: low level light therapy

06

What researchers measure

Primary outcomes

  1. Vocal Fatigue Measure: Vocal Fatigue Index (VFI-HK)

    The VFI(HK) contains 19 items in three domains (i) tiredness of voice and avoidance of voice use (ii) physical discomfort and (iii) improvement of symptoms after rest. All items are rated on a scale from zero (0, meaning "never") to four (4, meaning "always"). The score ranges from 0 to 76, with higher score indicating worst outcome.

    Time frame: This will be measured at baseline (pre-treatment) and within 2-weeks after the completion of treatment (post-treatment).

Secondary outcomes

  1. Vocal function measure: Voice Handicap Index - 30

    The VHI-30 contains 30 items in three subscales, namely "Functional", "Physical " and "Emotional". All items are rated on a scale from zero (0, meaning "never") to four (4, meaning "always"). The highest possible score for the VHI-30 is therefore 129, with the higher indicating worst scores.

    Time frame: This will be measured at baseline (pre-treatment) and within 2-weeks after the completion of treatment (post-treatment).

  2. Vocal Function Measure: Aerodynamic assessment

    Maximum phonation time will be used as the aerodynamic measure. Maximum phonation will be measured in seconds (time), with the higher score indicated better outcome.

    Time frame: This will be measured at baseline (pre-treatment) and within 2-weeks after the completion of treatment (post-treatment).

  3. Vocal Function Measures: Acoustic voice analysis

    Four parameters will be measures: (i) Jitter - Jitter represents the cycle-to-cycle variation in the fundamental frequency of the voice signal. Healthy, sustained phonation in young adults typically shows jitter values between 0.5% and 1.0%. Values above 1% may suggest dysphonia. (ii) Shimmer: Shimmer represents the cycle-to-cycle variation in the amplitude of the voice signal. Shimmer values below 3% are generally considered normal. Higher shimmer values can indicate dysphonia. (iii) Harmonic to noise ratio: HNR quantifies the ratio of harmonic to noise components in the voice signal. A high HNR indicates a strong presence of harmonics, which is characteristic of a clear, healthy voice. A low HNR suggests a greater proportion of noise in the voice, which is often associated with hoarseness. (iv) CPPS: CPPS measures the prominence of the cepstral peak, which represents the periodicity in the voice signal. Lower CPPS values suggest dysphonia.

    Time frame: This will be measured at baseline (pre-treatment) and within 2-weeks after the completion of treatment (post-treatment).

07

Study locations

1 site
  • The Chinese University of Hong Kong
    Shatin, N.T., Hong Kong
08

References and documents

Publications

  • Moreno M, Calvache C, Cantor-Cutiva LC. Systematic Review of Literature on Prevalence of Vocal Fatigue Among Teachers. J Voice. 2025 Jan;39(1):105-112. doi: 10.1016/j.jvoice.2022.07.029. Epub 2022 Sep 20. PubMed 36137877 ↗
  • Welham NV, Maclagan MA. Vocal fatigue: current knowledge and future directions. J Voice. 2003 Mar;17(1):21-30. doi: 10.1016/s0892-1997(03)00033-x. PubMed 12705816 ↗

Individual participant data

Plan to share: Yes — The data that support the findings of this study are available from the investigator, TL, upon reasonable request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: June 2025

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2024 to primary completion in May 2024, 2 months.

Of 30 interventional studies with no phase under Voice Disorders, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 48. This study's 2 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2025
First posted
Jul 14, 2025
StartActual
Mar 9, 2024
Primary completionActual
May 12, 2024
CompletionActual
Jun 12, 2024
Last update
Jul 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07062302
Responsible party
Thomas Law (Assistant Professor, Chinese University of Hong Kong) — Principal investigator
First posted
Jul 14, 2025
Start date
Mar 9, 2024
Primary completion
May 12, 2024
Completion
Jun 12, 2024
Last update
Jul 14, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion